B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti-dsDNA antibody in BALB/c mice by Ao HoHsieh et al.
HoHsieh et al. Arthritis Research & Therapy  (2017) 19:65 
DOI 10.1186/s13075-017-1268-2RESEARCH ARTICLE Open AccessB cell epitope of human cytomegalovirus
phosphoprotein 65 (HCMV pp65) induced
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Background: HCMV phosphoprotein 65 (HCMVpp65) is a putative immunogen that acts as an accelerator, inducing
autoantibody and exacerbating autoimmune response in susceptible animals. The immunity to pp65336-439
instigates autoimmunity, suggesting that pp65336-439 contains crucial B cell epitope(s) for the development of
nephritis. This study narrowed down the target epitope to pp65422-439 for immunization of BALB/c mice and
mapping of B cell epitope.
Methods: The target epitope pp65422-439 reactivity and B cell epitope mapping was examined in serum from
pp65422-439-immunized mice and patients with systemic lupus erythematosus (SLE). Kidney tissue from immunized
mice was examined for signs of immune complex nephritis.
Results: Anti-pp65422-439 antibody in serum either from patients with SLE or from pp65422-439-immunized mice
exhibited cross-reactivity to several nuclear components such as double-stranded DNA (dsDNA). Moreover, the
pp65422-439-immunized mice developed initial signs of glomerulonephritis such as deposition of immunoglobulin
G/M (IgG/IgM) and third complement component (C3). With B cell epitope mapping by pp65422-439-derived
decapeptides, one dominant epitope, pp65428-437, was identified in serum from pp65422-439-immunized mice and
patients with SLE with anti-pp65422-439 antibody. Epitope spreading from pp65428-437 to pp65430-439 was found in
pp65422-439-immunized mice in which we generated monoclonal antibodies to pp65425-434 and pp65430-439.
However, dsDNA positive reactivity was exclusively observed in Crithidia luciliae stains with pp65430-439-reactive
monoclonal antibody. Additionally, we observed the amelioration of autoimmunity following the elevation of IgM
targeting pp65428-437.
Conclusions: Our data suggest that pp65428-437 may be an autoimmune or lupus-prone B cell epitope and may
catalyze further epitope spreading for inducing autoantibodies in lupus-susceptible individuals.
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Systemic lupus erythematous (SLE) is a chronic auto-
immune disease characterized by widespread loss of
immune tolerance to self-antigens. Pathogen recognition
and subsequent immune responses are potentially the
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60 kD/Ro expression on the surface of human keratino-
cytes [11]. Immunization of lupus-prone mice by HCMV
recombinant glycoprotein B (gB) results in the production
of significant autoantibody to the U1-70 kDa spliceosome
protein [12]. Also, the significant correlation between anti-
body to HCMV and U1 small nuclear ribonucleoprotein
(snRNP) in HCMV-infected patients with SLE implies that
HCMV infection is associated with the development of
SLE [13]. In addition, immunization of BALB/c mice with
a surrogate octapeptide, DWEYSVWLSN, which induces
anti-dsDNA antibody, suggests that the shared structural
similarity of antigenic determinants among pathogens and
self-proteins leads to autoantibody production [14]. The
DNA-interacting amino acids of necrotic cells from post-
infected hosts may contribute to induction of anti-dsDNA
antibodies [15].
HCMV phosphoprotein 65 (pp65) is a viral scaffold
protein and the most abundant constituent of the extra-
cellular viral particle [16]. The pp65 is involved in
modulating viral kinase activity and attenuating host
antiviral responses [17, 18]. The pp65 protein is a target
of both cellular and humoral immunity in healthy indi-
viduals, but dominant T cell epitope(s) leads to the ro-
bust cellular responses such as cytotoxic T lymphocyte
response [19, 20]. Highly elevated anti-pp65 titers in pa-
tients with SLE and immunization of NZB/W F1 mice
by pp65 induces early onset of lupus-like symptoms, im-
plying a potential role of pp65 in SLE [21].
The immunization of truncated pp65336-439-conjugated
C3d has been shown to induce lupus-like autoantibodies
and subsequent development of autoimmunity [22]. The
current study aims to further identify the autoantibody-
inducing B cell epitope(s) within pp65386-439 and the po-
tential pathogenic immune response.
Methods
Characteristics of the study populations
All patients were recruited from the clinics of Chang Gung
Memorial Hospital, and rheumatology specialists confirmed
that all patients fulfilled the 1982 and 1997 American College
of Rheumatology (ACR) diagnostic criteria for SLE [23, 24]
This study was approved by the Institutional Review Board
of Chang Gung Medical Foundation. The study of methods
was carried out in accordance with the relevant guidelines
and informed consent was obtained from all subjects.
Mice
Normal female BALB/c mice, 3–5 weeks old, were pur-
chased from the National Laboratory Animal Center
(NLAC), Taiwan. Animals were housed in a pathogen-free
facility with an independent ventilation cage system at the
laboratory animal center of Chang Gung Memorial
Hospital. All BALB/c mice were 8 weeks old at inoculation.Synthetic peptides
For all synthetic peptides, the purity of the peptide was
>95%, per the peptide manufacturer (GenScript, NJ,
USA). The preparation of peptides followed the manu-
facturer’s instructions (20 μg/μl), with storage at -80 °C
prior to use. Six histidines and one cysteine were added
at the C terminus of the peptide as a target or for cross-
linking to a carrier protein via a disulfide bond.
Plasmid construction
The full-length pp65 sequence was amplified from pCMV6-
pp65 (SKU VC101263, Origene, FJ527563) using the follow-
ing paired primers (forward 5′GCGGATATCATGGA-
GAGCCGGGGCCGG, reverse 5′ GCGGGATCCGCCTCT
ATGCTTCTTGGG). The pp65 sequence was prepared
from PCR and digested by EcoRV/BamHI, then ligated
into pET30. The murine C3d encoding sequence
(GenBank: DQ408205) was PCR-amplified with C3d
primers (forward 5′CGCGGATCCATGACCCCCGCA
GGCTGTGGG, reverse 5′CGCGCTCGAGGCTACGG
CTGGGGAGGTG) and ligated into pET30.
Antigen preparation
The C3d biotinylation (Pierce, Thermo Scientific, IL,
USA) and streptavidin (SA) (Pierce) conjugation were
performed as per the manufacturers’ protocol. In brief,
maleimide-activated streptavidin (Pierce) was conjugated
with peptide containing reduced disulfide bonds from a
disulfide reducing gel (Pierce) and mixed with biotinyl-
ated C3d to form the peptide-SA-biotin-C3d tetramer,
including pp65386-403, pp65422-439 and SA-C3d only. Tet-
ramers were generated and prepared for immunization
within 4 hours.
Immunization and serum collection
Female BALB/c mice (n = 28) were randomly separated
into groups receiving pp65386-403- (n = 9), pp65422-439-
C3d (n = 9), SA-C3d (n = 5) or PBS (n = 5). Mice were
inoculated subcutaneously with 100 μg (2 μg/μl)
pp65386-403-C3d, pp65422-439-C3d, SA-C3d or 50 μl PBS
in complete Freund’s adjuvant (CFA, Sigma Aldrich,
MO, USA) at day 0, respectively. Boosting was per-
formed with antigens in incomplete Freund’s adjuvant
(IFA, Sigma Aldrich) at day 14, day 28 and day 42. Mice
were bled via the retro orbital vein one day prior to each
assay and at 2-week intervals. Unused serum was stored
at -80 °C and the PBS-diluted seruma was kept at 4 °C.
Antibody preparation, biotinylation and streptavidin
conjugation
Recombinant proteins were over-expressed in Escherichia
coli with 1 mM isopropyl β-D-thiogalactoside induction
(IPTG, Sigma Aldrich) and purified by a nickel affinity col-
umn (Sigma Aldrich). Antibody preparation was performed
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bromide (CnBr) powder (Sigma Aldrich) was activated fol-
lowing the manufacturer’s protocol. A total of 2 mg of four
tandem repeats of the pp65422-439 peptides (GGGSGGGA-
MAGASTSAGRKRKS) was dissolved by gentle rotation in
a coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3)
with activated CnBr gel at 4 °C overnight. The free active
groups on CnBr were deactivated by 0.1 M Tris-HCl
(pH 8.0) at room temperature (RT) for 2 hours. After de-
activation, CnBr gel was washed with alternating buffer
(0.1 M NaAc, 0.5 M NaCl, pH 4.0 and 0.1 M Tris-HCl,
0.5 M NaCl, pH 8.0) twice and washed with 10 ml PBS
once. For purification, 10 ml of serum from twenty
dsDNA-positive or dsDNA-negative patients with SLE with
pp65422-439 antibody in 20 ml PBS, respectively, were added
to pp65422-439-conjugated CnBr gel and rolled at 4 °C over-
night. The flow-through was collected and concentrated as
a negative control, while bound antibodies were eluted by
1 ml of 0.1 M glycine (pH 2.0). The eluted samples were
neutralized immediately with 30 μl of neutralizing buffer
(1 M Tris-HCl, 2 M NaCl, pH 8.8).
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as previous described [22]. Briefly,
for the anti-pp65 peptide (pp65386-439, pp65386-403,
pp65396-413, pp65404-421, pp65414-431, pp65422-439 and nine
pp65422-439-derived decapeptides) or anti-dsDNA antibody
assay, 1 μg/well of synthetic peptide or purified calf
thymus dsDNA (Sigma Aldrich) in coating buffer
(150 mM Na2CO3, 150 mM NaHCO3, pH 9.6) was coated
to a microtiter 96-well plate (Greiner Bio-One, CA, USA)
at 4 °C overnight. After blocking with 5% skimmed milk,
250× diluted human or mice serum, 3 μg purified pp65422-
439 antibody or 1 μg monoclonal antibodies in PBS were
added and incubated at 37 °C for 2 hours.
For the competitive inhibition assay, anti-pp65422-439
purified antibody was co-incubated with 1 μg pp65422-439
or dsDNA in 200 μl PBS at RT for one hour. The mix-
ture was transferred to one well of a 96-well plate coated
with dsDNA or pp65422-439 for incubation at 37 °C for
2 hours. At the end of the incubation, the microtiter
plate was washed four times with PBST (PBS with 0.05%
Tween 20) and bound antibody was detected by horse-
radish peroxidase (HRP)-conjugated anti-human/mouse
G/M or anti-mouse IgG subclasses (IgG1, IgG2a, IgG2b
and IgG3) at a dilution of 1:5000 (Jackson ImmunoRe-
search Laboratories, PA, USA) at 37 °C for 2 hours. For
detection of cross-reactivity to host proteins, 1 μg/well
of homogenized HEK293T cell lysate was coated on a
microtiter plate at 4 °C overnight. After blocking, mice
serum was diluted and bound antibodies were detected
as described above. O-phenylenediamine dihydrochlor-
ide (OPD, Sigma Aldrich) was used as the substrate in
ELISA buffer (250 mM Na2HPO4, 175 mM C6H8O7,pH 5.0) and HRP activity was read at 450 nm with a
micro ELISA reader (Molecular Devices).
Western blot/slot blot
Full-length pp65 protein (40 μg/per gel) was separated
by 12% SDS-PAGE (slab gel format). Separated protein
was transferred to nitrocellulose paper, blocked by 5%
skimmed milk and then analyzed with 1 μg/ml anti-His-
tag antibody (eBioscience, CA. USA), 100× diluted hu-
man sera or 3 μg purified pp65422-439 antibody in PBS at
RT for 2 hours. Antibody reactivity was detected by
HRP-conjugated secondary antibody (Jackson Immu-
noResearch Laboratories) and chemiluminescent detec-
tion reagent (Millipore, MA. USA).
Anti-nuclear antibodies, C. luciliae and kidney
immunofluorescence stain
Mouse serum was tested for anti-nuclear antibodies
(ANAs) at 1:100 dilutions in PBS using a standard
anti-nuclear antibody (ANA) test (Diasorin, Saluggia, Italy).
The reactivity of anti-dsDNA antibody was examined by
immunofluorescence stain using the C. luciliae test
(Diasorin) at dilutions of 1:20, 1:40 and 1:80 in PBS, as per
manufacturer’s instruction. In brief, 30 μl of diluted mice
serum, 3 μg purified pp65422-439 antibody or 1 μg monoclo-
nal antibodies were incubated on a slide coated with HEp-2
or C. luciliae at RT for 30 minutes in a humidified chamber.
Slides were washed three times in 50 ml PBS at RT for
10 minutes each.
Bound antibodies were detected by 100× diluted FITC-
conjugated anti-mouse IgG/M (Jackson ImmunoResearch
Laboratories) at RT for 30 minutes in a darkened and
humidified chamber. For nuclear visualization, the HEp-2
slide was incubated in 30 μl of 4',6-diamidino-2-phenylin-
dole (DAPI) (1 mg/ml, Sigma Aldrich) at RT for 5 minutes
in the dark. At the end of staining, slides were washed with
PBS for 30 seconds and mounted via mounting medium
(Diasorin) for investigation by fluorescence microscopy
(Olympus DP72). For immunofluorescence staining of the
glomerulus, kidneys were removed from the mice, immedi-
ately placed in optimal cutting temperature (OCT) gel and
frozen at -80 °C for 24 hours. The 5-μm-thick frozen
sections were stained with FITC-conjugated anti-mouse
IgM/G (Jackson ImmunoResearch Laboratories) at a 1:100
dilution in PBS at RT for 30 minutes in a humidified
chamber in the dark. After PBS washing, coverslips with
mounting medium (Diasorin) on tissue slides were pre-
pared for investigation by fluorescence microscopy.
Hybridoma preparation
The hybridoma was prepared following the manufacturer’s
instructions (Roche, Basel, Switzerland) with minor modi-
fications. Briefly, the mouse spleen cells were mixed at a
ratio to Sp2/0-Ag14 of 5:1 (ATCC, VA, USA) in a sterile
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cells at 800 rpm for 10 minutes. After discarding the
supernatant, 1 ml of 50% PEG 1500 (Roche) was slowly
added to the cell pellet dropwise over a 1-minute period
and the cells were swirled for 90 seconds in a 37 °C water
bath. Cell fusion was stopped by adding Roswell Park Me-
morial Institute medium (RPMI) 1640 (Gibco, CA, USA)
containing 10% fetal bovine serum (FBS, Invitrogen, CA,
USA) with gentle swirling at RT for 10 minutes. After
washing with RPMI 1640 twice, cells were suspended in
30 ml of RPMI1640 supplemented with 10% FBS, 10% BM
Condimed H1 (Roche) and 1x HAT (Gibco), plated 2.5 ml
per well in a 6-well culture dish and incubated at 37 °C in
a 5% CO2 incubator. Limiting dilution was carried out for
selection of a single colony, which was amplified in RPMI
1640 supplemented with 10% FBS, 10% BM Condimed
H1 (Roche), 1× HT (Gibco) and 1x hybridoma fusion &
cloning supplement (Roche). The supernatant was har-
vested for ELISA of antibody activity to pp65422-439.
Statistical analysis
Statistical differences in titer and prevalence were ana-
lyzed using GraphPad Prism (GraphPad Software Inc.).
The Student t test, two-tailed Fisher’s test, and Mann-
Whitney test were used for these comparisons with
graphs depicting mean ± SEM. A 5% level of significance
for p values was used for all analyses.
Results
Elevated anti-pp65422-439 reactivity related to dsDNA
positivity in SLE
The fragment of pp66336-439 induced autoantibodies and
immunoglobulin (Ig) deposition on glomeruli in BALB/c
mice has been reported [22]. Due to a poor humoral
response to pp65336-385 in patients with SLE, we examined
anti-pp65386-439 reactivity to reveal the critical B cell epi-
topes using serum from 238 patients with SLE (119 with
and 119 without anti-dsDNA reactivity), 86 patients with
ankylosing spondylitis (AS), 78 patients with rheumatoid
arthritis (RA) and 84 healthy controls. As shown in Table 1,
83 of 238 patients with SLE (34.87%) had higher incidence
of antibody reactivity to pp65386-439 compared to the 1/86
patients with AS (1.16%), 4/78 patients with RA (5.28%) orTable 1 The prevalence of antibody to HCMVpp65386-439 in patients
SLE-dsDNA(+) S
Age (years) 16-77 2
Mean (years) 39.5 3
Total specimen 119 1
Female (%) 100 1
Responsiveness pp65386 to 439 (%) 52/119 3
(43.70) (
RA: rheumatoid arthritis; AS: ankylosing spondylitis1/84 normal controls (1.20%). Of the 119 Patients with SLE
with anti-dsDNA positive serum (termed SLE-dsDNA(+)),
52/119 patients were also positive for anti-pp65386-439 activ-
ity (43.70%). On the other hand, 31/119 patients with SLE
with anti-dsDNA negative sera (termed as SLE-dsDNA(-))
(26.05%) were anti-pp65386-439 positive. Human serum posi-
tive for pp65386-439 was reconfirmed by western blotting
(Additional file 1: Figure S1).
Next, we synthesized pp65386-403, pp65404-421 and
pp65422-439, covering the entire pp65386-439, and re-screened
serum from patients with SLE and healthy controls using
ELISA to identify the dominant epitope(s). As shown in
Fig. 1, in the SLE subgroups there was significant elevation
of IgG antibody to pp65422-439 (SLE-dsDNA(+) 0.254 ±
0.014, p < 0.001; SLE-dsDNA(-), 0.186 ± 0.009, p = 0.026)
and pp65404-421 (SLE-dsDNA(+), 0.180 ± 0.011, p = 0.004;
SLE-dsDNA(-), 0.151 ± 0.008) compared to normal controls
(0.156 ± 0.009; 0.144 ± 0.005). The IgG antibody titer for
pp65422-439 was greater than that for pp65404-421 in the SLE
subgroups (SLE-dsDNA(+), p < 0.001; SLE-dsDNA(-), p =
0.003). Moreover, SLE-dsDNA(+) had greater anti-pp65422-
439 reactivity than SLE-dsDNA(-) (p < 0.001).
In further epitopes analysis, antibody against pp65422-439
was significantly elevated in patients with SLE-dsDNA(+)
compared to pp65396-413 (0.163 ± 0.005, p < 0.001) or
pp65414-431 (0.180 ± 0.01, p = 0.016). On the other hand,
we were unable to purify anti-pp65422-439 antibody using
CnBr conjugated with four tandem repeated pp65422-439
peptide from disease or healthy controls, suggesting that
the lower titer of anti-pp65422-439 antibody is unavailable
for purification. Together, these findings suggested anti-
pp65422-439 reactivity is specific to patients with SLE and
related to dsDNA positivity.
Anti-pp65422-439 antibody showed cross-reactivity to
nuclear proteins and dsDNA
To elucidate the relationship between pp65422-439 and
autoantibodies developed in patients with SLE, antibodies
to pp65422-439 were affinity-purified in pooled serum from
SLE-dsDNA(+) or SLE-dsDNA(-). The anti-pp65422-439
antibodies from both SLE subgroups exhibited anti-pp65
activities (Fig. 2a). The purified anti-pp65422-439 antibodies
could be inhibited by pp65422-439 or partially inhibited bywith autoimmunity and healthy controls
LE-dsDNA(-) AS RA Normal
2-75 15-66 20-89 32-64
5.2 37.1 56.2 43.2
19 86 78 84
00 18 82 100
1/119 1/86 (1.16) 4/78 (5.13) 1/84 (1.19)
26.05)
Fig. 1 Detection of IgG antibody against pp65422-439 subfragments by serum from patients with systemic lupus erythematosus (SLE) and healthy
controls. ELISA was performed for IgG against five pp65 subfragments, pp65386-403, pp65396-413, pp65404-421, pp65414-431 and pp65422-439, using
serum from patients with SLE with or without anti-double-stranded DNA antibody (SLE-dsDNA(+), n = 119; SLE-dsDNA(-), n = 119) and normal
controls (n = 84). 250× diluted sera were used. Data are presented as the mean ± SEM of three independent experiments. O.D. optical density
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reactivity of anti-pp65422-439 antibody to dsNDA suppressed
by pp65422-439 or dsDNA in the two SLE groups (Fig. 2c).
Notably, the titer of anti-dsDNA antibody was significantly
higher in SLE-dsDNA(+) (0.833 ± 0.056) than in SLE-
dsDNA(-) (0.418 ± 0.037, p = 0.004; Fig. 2c). However, the
anti-dsDNA activity was solely exhibited by C. luciliae stain
with anti-pp65422-439 antibody from SLE-dsDNA(+)
(Fig. 2d). Indirect immunofluorescence stain on purified
serum from patients with SLE revealed clear speckle stains
(Figs. 2e1, e4). Notably, stain from nucleosome/chromatin
is unique to pp65422-439 specific antibody from SLE-dsDNA(+) (Fig. 2e2, e5). In contrast, no nuclear responses
were observed in normal serum stain (Fig. 2e3, e6).
The pp65422-439 immunization induced cross-reactive
antibodies to nuclear components
To evaluate the induction of autoantibodies following
exposure of pp65422-439, BALB/c mice were immunized
with pp65422-439, pp65386-403, streptavidin (SA) or PBS,
using mouse C3d as a molecular adjuvant to improve
the immunogenicity of these peptides through CR2-C3d
interaction [22, 25]. Both pp65422-439 and pp65386-403
immunization induced anti-pp65386-439-reactive IgG at
Fig. 2 Detection of cross-reactivity in affinity-purified pp65422-439-specific IgG in serum from patients with systemic lupus erythematosus (SLE). a
Immunoblot analysis with serum from patients with SLE, healthy controls and anti-pp65422-439 antibody from ten pooled SLE-double-stranded
DNA (SLE-dsDNA(+) or SLE-dsDNA(-)) serum against human cytomegalovirus (HCMV)pp65. We used 100× diluted serum from patients with SLE or
healthy controls and anti-His-tag antibody as positive and negative controls. Molecular mass markers (kD) are shown on the left. MW molecular
weight, kDa kilodalton. b-c ELISA for anti-pp65422-439 and anti-dsDNA activity: 100× diluted normal serum and 3 μg anti-pp65422-439 antibody
from SLE-dsDNA(+) or SLE-dsDNA(-) sera were used. For the competitive inhibitory assay, 1 μg/well of pp65422-439 or dsDNA was used. d
Representatives of C. luciliae stain by 100× diluted serum from SLE-dsDNA(+) (d1) or healthy control and anti-pp65422-439 antibody (d2) from
SLE-dsDNA(+) (d3) or SLE-dsDNA(-) (d4) serum. White arrowheads indicate the positive stains. e HEp-2 substrate slides were used for detection
of anti-nuclear antibodies. Patterns of speckle (e4) and nucleosome/chromatin (e2, e5) stains were revealed by anti-pp65422-439 antibody from
SLE-dsDNA(+) or SLE-dsDNA(-) serum. Nuclear reactivity was not observed from 100× diluted normal serum (e3, e6). White arrowheads indicate
the patterns of nuclear response. These results are representative of triplicated experiments. O.D. optical density
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completion of the observation period (14 weeks post
immunization). Quasi-quantitative analysis showed that
the pp65422-439 induced twice as much of pp65386-439-
specific antibody titers than pp65386-403. The anti-
pp65386-439 reactive IgG was not detected from either
SA-C3d or PBS immunized mice (Fig. 3a and Additional
file 2: Figure S2).
The serum from pp65 epitope immunization was tested
against HEK293T cell lysate. The immunization of pp65422-
439 or pp65386-403 elicited anti-HEK293T IgG, which was
first detected at 6 weeks (data not shown), peaked at
8 weeks and was sustained until 14 weeks post
immunization. The pp65422-439 immunization (0.667 ±0.027) induced higher titers than pp65386-403 immunization
(0.447 ± 0.034, p < 0.001) at 8 and 14 weeks post
immunization (Fig. 3b). Multiple ANA patterns can be
identified following immunization of pp65422-439 (Fig. 3c)
including speckle (Fig. 3c1, c11), nuclear rim (Fig. 3c2, c12),
chromatin/nucleosome (Fig. 3c3, c13), centrioles (Fig. 3c4,
c14), MSA I (Fig. 3c5, c15), MSA II (Fig. 3c6, c16), nuclear
dots (Fig. 3c7, c17), nuclear envelope (Fig. 3c8, c18) and
cytoplasmic proteins stains (Fig. 3c9, c19) at 1:100 dilution
8 weeks post immunization (Additional file 3: Table S1).
Immunization with pp65386-403 induced a pattern of nuclear
dots but it was only detected at 1:40 dilution (data not
shown). Nuclear staining was not observed in control mice
at 1:40 or higher dilution (Fig. 3c10, c20). Antibodies
Fig. 3 Detection of anti-pp65 and anti-nuclear reactivity from pp65386-403, pp65422-439, streptavidin-complement C3 (SA-C3d) or PBS-immunized
serum. The IgG against pp65386-439 and HEK293T extract from pp65386-403 (n = 9), pp65422-439 (n = 9), SA-C3d (n = 5) or PBS (n = 5)-immunized
serum at 0, 4, 8 and 14 weeks post immunization were performed at 1:250 dilution. a ELISA for anti-pp65386-403 and anti-pp65422-439 reactivity
against pp65386-439 peptide. b ELISA for anti-HEK293T reactivity against total HEK293T lysate. c HEp-2 substrate slides were used for detection of
anti-nuclear antibodies. Serum 8 weeks post immunization was 100× diluted for anti-nuclear antibodies (ANA) stain. Nuclear patterns of speckle
(b1, b11), nuclear rim (b2, b12), chromatin/nucleosome (b3, b13), centriole (b4, b14), mitotic spindle type I (MSA-I) (b5, b15), MSA-II (b6, b16), nuclear
dot (b7, b17) and nuclear envelope (b8, b18) were revealed in serum from pp65422-439-immunized mice. Cytoplasmic response (b9, b19) was
detected in serum from pp65386-403-immunized and pp65422-439-immunized mice. Nuclear reactivity was not found in PBS, SA-C3d or pp65386-403-
immunized mice (b10, b20). White arrowheads indicate the patterns of nuclear or cytoplasmic response. Data are presented as the mean ± SEM of
three independent experiments. w weeks post immunization, O.D. optical density
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of nine pp65422-439-immunized mice (78%) and three out of
nine pp65386-403-immunized mice (33%) at 1:100 dilution.
Immunization of pp65422-439 induced high titers of
anti-dsDNA antibodies.
Anti-dsDNA antibody is pathognomonic for SLE. To
verify the cross-reactivity of anti-pp65422-439 antibodies
to dsDNA, anti-dsDNA reactivity from immunized
animals was tested by both anti-dsDNA ELISA and C.
luciliae assays. In the ELISA, the pp65422-439 immunized
mice exhibited significantly higher titers of IgG to
dsDNA compared to pp65386-403 immunization (Fig. 4a).
The anti-dsDNA titers were not elevated in theremaining groups. Isotype analysis of pp65422-439
immunization showed that the enhancement of anti-
dsDNA is likely contributed by IgG1 (dsDNA(+) vs.
dsDNA (-), 0.44 ± 0.05 vs. 0.32 ± 0.02, p = 0.049) and
IgG3 (dsDNA(+) vs. dsDNA (-), 0.295 ± 0.01 vs. 0.217 ±
0.03, p = 0.043) (Fig. 4b). In the C. luciliae stain, three
serial dilutions, 1:20, 1:40 and 1:80 were used (Fig. 4c
and Table 2). At the lowest dilution (1:20), anti-dsDNA
activities were detected from all groups.
The anti-dsDNA activities from controls and pp65386-
403 gradually disappeared during serial dilutions to 1:40
or 1:80. In contrast, after pp65422-439 immunization, 8/9
and 5/9 positive rates were detected at 4 weeks at 1:40
and 1:80 dilutions, respectively. None of the animals
Fig. 4 Detection of serum anti-double-stranded DNA (anti-dsDNA) antibody and immunoglobulin deposition in glomeruli from immunized mice.
a ELISA for anti-dsDNA activity with serum at 1:250 dilution. b Isotyping of anti-dsDNA antibody for pp65422-439 immunized mice (n = 9) at 8 weeks
post immunization. Serum was used at 1:250 dilution. dsDNA(+) seropositive for dsDNA, dsDNA(-) seronegative for dsDNA. c Representatives of C.
luciliae stain by serum from pp65422-439 (c1), pp65386-403 (c2), streptavidin-complement 3d (SA-C3d) (c3) or PBS (c4) immunized animals at 8 weeks
post immunization at 1:80 dilution. White arrowheads indicate dsDNA-positive stains. d Kidney sections from pp65422-439- immunized mice were
stained with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (d1), IgM (d2) and C3 (d3). Immunoglobulin deposition was not
observed in glomeruli from SA-C3d-immunized (d4) or PBS-immunized mice. e Kidney sections from pp65422-439-immunized mice were stained
with FITC-conjugated anti-mouse IgG1 (e1), IgG2a (e2) IgG2b (e3) and IgG3 (e4). Kidneys were collected at 22 weeks of mice age. Data are
presented as the mean ± SEM of three independent experiments. w weeks post immunization, O.D. optical density
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activity at 8 weeks post immunization. One animal with
pp65386-403 immunization had activity to dsDNA at 1:20
and 1:40 dilutions but this disappeared at 1:80 dilution.
In pp65422-439 immunization, 9/9, 6/9 and 5/9
anti-dsDNA serum was identified at 1:20, 1:40 and 1:80
dilutions, respectively. At 14 weeks post immunization,
all animals except those with pp65422-439 immunization
had negative dsDNA reactivity. The dsDNA reactivity of
pp65422-439 immunization at 14 weeks post immunization
was reduced to 4/9, 3/9 and 2/9 at 1:20, 1:40 and 1:80
dilutions, respectively.
To study the pathogenicity of pp65422-439 reactive anti-
bodies, kidney tissue from immunized mice was examined
for signs of immune complex nephritis. Indirect immuno-
fluorescent stains with anti-mouse IgG or IgM revealed
that pp65422-439-immunized mice developed intense IgG
(6/9), IgM (5/9) and C3 (2/9) deposition in the glomeruli
(Fig. 4d and Additional file 3: Table S2). In contrast topp65422-439, pp65386-403 immunization induced only mild
IgM deposition (2/9). No pathological staining was found
in PBS (0/5) or SA-C3d immunized mice (0/5). Immuno-
globulin isotype deposition in pp65422-439-immunized
mice revealed that IgG1 (6/9) and IgG3 (4/9) were domin-
ant isotypes compared to IgG2a (2/9) and IgG2b (1/9) in
pp65386-403-immunized mice (Fig. 4e).
The dominant target of HCMV pp65428-437 epitope
exhibited dsDNA reactivity
In order to map the B cell epitopes within pp65422-439,
nine pp65422-439-derived decapeptides were synthesized
and tested with SLE-dsDNA(+) serum and serum from
immunized animals (Fig. 5a). Monoclonal antibodies were
also generated from animals immunized with pp65422-439.
We observed pp65422-439-specific reactive monoclonal
antibodies (mAb) against pp65430-439 (P1, P2) and
pp65425-434 (P3, P4) (Fig. 5b). The P1 and P2 mAbs also
reacted positively in the ELISA and C. lucilliae assay
Table 2 Summary of anti-dsDNA activity in immunized mice
Weeks post immunization PBS n=5 SA-C3d n=5 pp65386-403 n=9 pp65422-439 n=9
4 2w/5, 2w/5, 0/5 3w/5, 3w/5, 0/5 3(2,1w)/9, 3(1,2w)/9, 0/9 8/9, 8(5,3w)/9, 5(4,1w)/9
8 0/5, 0/5, 0/5 0/5, 0/5, 0/5 2(1,1w)/9, 1w/9, 0/9 9(8,1w)/9, 6(5,1w)/9, 5/9
14 0/5, 0/5, 0/5 0/5, 0/5, 0/5 0/9, 0/9, 0/9 4(2,2w)/9, 3(2,1w)/9, 2/9
Mice sera were used at dilution of 1:20, 1:40 or 1:80. W: weak response
HoHsieh et al. Arthritis Research & Therapy  (2017) 19:65 Page 9 of 14(Fig. 5c, d). In human serum assays, pp65426-437, which ex-
pands three decapeptides, is targeted by anti-pp65422-439-
specific antibody from SLE-dsDNA(+) (Fig. 5e).
In immunized animals, pp65422-439-induced IgM reacted to
all decapeptides with elevated titers to pp65425-434 at 4 weeks
post immunization (Fig. 6a). In addition to pp65425-434, few
mice also have elevated IgM to pp65428-437 and pp65429-438.
At 8 weeks post immunization, IgM activity in response to
decapeptides was enhanced roughly twofold optical density
(OD) with the exception of pp65428-437, which almost tripled
the OD at week 4 (Fig. 6a and b). The IgM activities in re-
sponse to decapeptides at 14 weeks post immunization were
reduced to an OD level similar to week 4. The IgG at 4 weeks
post immunization was greatly enhanced in response to
pp65428-437 in all mice but there was poor response toFig. 5 Antibody activity against pp65422-439-derived decapeptides and dou
systemic lupus erythematosus (SLE), immunized mice serum and monoclon
nine overlapping pp65422-439-derived decapeptides. Each peptide is shifted
monoclonal antibodies (b) and anti-pp65422-439 antibody (c) from SLE-dsDN
used as negative controls. d ELISA for IgG against pp65422-439 and dsDNA w
e Representatives of C. luciliae stain by P1 (e1), P2 (e2), P3 (e3) or P4 (e4) mo
positive stains. Data are presented as the mean ± SEM of three independenpp65425-434 (Fig. 6c). At 8 weeks post immunization, anti-
pp65428-437 IgG represented the dominant immune activity,
followed by anti-pp65430-439 and anti-pp65429-438 IgG (Fig. 6d).
At 14 weeks post immunization, the IgG activities in re-
sponse to pp65430-439 and pp65425-434 were further enhanced
and associated with drastic reduction of anti-pp65428-437 to
its basal level. This reduction of anti-pp65428-437 IgG to basal
level occurred universally in all of the animals of this group.
Discussion
Viral peptide-induced autoimmunity in animal models is
an emerging field but the underlying mechanisms are not
well-understood. Immunization of EBNA-1 or its
fragment has been demonstrated to elicit not only im-
mune response to viral antigen, but also IgG activity to 60ble-stranded DNA (dsDNA) from anti-pp65422-439 antibodies in human
al antibodies from pp65422-439-immunized mice. a Representatives of
by one amino acid. ELISA for anti-decapeptide reactivity with four
A(+) serum: 100× diluted normal serum and flow-through were
ith monoclonal antibodies and 100× diluted normal serum.
noclonal antibodies, respectively. White arrowheads indicate the
t experiments. O.D. optical density
Fig. 6 ELISA for IgG/M reactivity against decapeptides from pp65422-439-immunized serum. Nine pp65422-439 derived decapeptides and 250×
diluted mice serum was used. a ELISA for IgM against decapeptides from pp65422-439-immunized mice (n = 9) at 4, 8 and 14 weeks post
immunization. b The IgM against nine decapeptides from each pp65422-439-immunized mice (n = 9) at 8 weeks post immunization; IgM reactivity
to each pp65422-439-derived decapeptide. c ELISA for IgG against decapeptides from pp65422-439-immunized mice (n = 9) at 4, 8 and 14 weeks
post immunization. d IgG against decapeptides from pp65422-439-immunized mice (n = 9) at 8 weeks post immunization: IgG reactivity to each
pp65422-439-derived decapeptide. *IgM/G against pp65428-437. Data are presented as the mean ± SEM of three independent experiments. O.D.
optical density, M mouse
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the high prevalence of serum anti-pp65422-439 antibody in
patients with SLE. Also, immunization of BALB/c mice
with pp65422-439-induced cross-reactive autoantibodies
against nuclear antigens of host cells, particularly dsDNA,
and developed initial signs of nephritis with Ig deposition
at 14 weeks post immunization. However, our mapping is
unable to completely exclude the possibility that there
were discontinuous epitopes, because the B cell epitopes
were examined from pp65386-439 to pp65422-439. The
higher incidence of anti-pp65422-439 activity in patients
with SLE and the instigation of autoimmune-like anti-
bodies through immunization of pp65422-439 in BALB/c
mice suggested that immunity to pp65422-439 might drive
pathogenic potential for SLE through epitope spreading
and triggering autoantibody production in genetically
susceptible individuals.
In our competitive inhibitor assay (Fig. 2b, c), pp65422-
439 antibody from SLE-dsDNA(+) cross-reactive with
dsDNA was not inhibited completely by pp65422-439,
suggesting that more complex antibody repertoires,
for example antibodies that recognize discontinuous
epitopes, were obtained from SLE-dsDNA(+) through
affinity purification by four tandem-repeats of pp65422-439.In addition, pp65422-439 antibody from SLE-dsDNA(-)
exhibited anti-dsDNA reactivity, but was negative on
C. luciliae stain. These results were suggested that the
anti-dsDNA activity in the ELISA might be due to rela-
tively weak anti-dsDNA reactivity of concentrated anti-
pp65422-439 antibody from SLE-dsDNA(-). On the other
hand, the increase in antibodies to HEK293 and dsDNA
observed in SA-C3d-immunized mice at 8 week post-
immunization might result from polyclonal B cell activation.
However, we did not observe this phenomenon in our
analysis of anti-pp65422-439 antibody against pp65386-439.
The absorption and analysis of the B cell repertoire in
response to pp65422-439 may play a critical part in auto-
immunity require further validation.
HCMVpp65 is a well-known T cell antigen in healthy in-
dividuals [19, 20]. HCMV pp65 and pp65336-439-induced
weak humoral responses were verified in healthy humans
and BALB/c mice [21, 22]. Unlike normal or other disease
controls, anti-pp65422-439 antibody occurs more frequently
and has higher specificity in patients with SLE, particularly
in anti-dsDNA-positive patients. Elevated anti-pp65336-439
antibody titers were measured in patients with SLE, but
there was no statistically significant relationship between
anti-pp65336-439 reactivity and serum dsDNA antibody [22].
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one more representative epitope, which is associated
with the production of anti-dsDNA antibody. Regarding
the improvement of immunogenicity of pp65 peptides in
the BALB/c model, mouse C3d acts as molecular adju-
vant for interplay between innate and adaptive immunity
[25]. Immunization of truncated pp65336-439 attached to
C3d has been demonstrated to induce the development
of autoimmunity [22]. In contrast, complete Freund’s
adjuvant alone was unable to elicit chronic autoimmun-
ity (data not shown). Immunization of pp65422-439 with
C3d to BALB/c mice was sufficient to induce anti-
pp65422-439 antibody. The transient humoral response to
pp65422-439, also observed in pp65336-439-immunized
BALB/c mice, indicates that genetic background plays a
vital role in exacerbation of SLE.
Anti-dsDNA antibody has served as a critical immuno-
logical biomarker and diagnostic criterion for SLE [23, 24].
BALB/c mice challenged by a surrogate peptide have been
reported to induce anti-dsDNA antibodies [14]. The
nephritogenicity of anti-dsDNA antibody has been shown
to mediate cross-reactivity to alpha actinin and annexin II
[28, 29]. Also, lupus autoantibodies binding to DNA/nu-
cleosome fragments released from apoptotic cells were ob-
served in the glomerular matrix [30]. Immunization using
pp65 or its truncated form has been previously shown to
induce multiple anti-nuclear antibodies and anti-dsDNA
antibody in BALB/c mice [22]. As expected, anti-dsDNA
serum from patients with SLE had anti-pp65 reactivity, par-
ticularly to the pp65422-439 region. Notably, patients with
SLE were double positive to pp65, and simultaneously
dsDNA chromatin/nucleosome stain was positive. The
anti-pp65 antibody that reacted to dsDNA and chromatin/
nucleosome was previously verified in animals immunized
for pp65336-439 [22].
It has been suggested that anti-nucleosome antibodies are
sensitive and specific for lupus nephropathy and the correl-
ation of the antibody titers represent a better biomarker of
SLE global disease activity [31, 32]. These consistent results
of human and animal studies imply that pp65422-439 peptide
may possess one critical epitope contributing to the develop-
ment of SLE. However, the limitations of the present study
using stored serum from a cross-sectional study require fu-
ture study to document their clinical associations with lupus
nephropathy and the SLE disease activity damage index.
Following immunization of pp65422-439, antigen-
specific IgG and IgM were analyzed at 4, 8 and 14 weeks
post immunization. This pp65422-439 immunization
scheme elicited antibodies reactive against antigens
from HEK293T cells and produced ANA stain patterns
resembling those found in anti-pp65422-439-purified
antibody stains from patients with SLE. The appearance
of autoantibodies in patients with SLE is an indicator of
subsequent lupus disease onset [33]. The anti-dsDNAantibodies play critical roles in lupus nephritis; however,
elevation of autoantibodies, particularly anti-dsDNA
antibodies, has been identified in double-transgenic
BALB/c mice expressing both the R4A-gamma2b heavy
chain and the anti-apoptotic bcl-2 gene, but the mice
did not develop nephritis [34]. In the current study
ELISA and the C. luciliae assay demonstrated anti-
dsDNA reactivity to pp65-purified human antibodies
and pp65422-439-immunized serum. The pp65422-439
immunization scheme not only elicited anti-dsDNA
antibodies, but also initiated early-phase kidney dam-
age in BALB/c mice. In the near future, we speculate
that pp65422-439 reactivity in combination with anti-
chromatin/nucleosome and dsDNA antibodies may
better fit as a surrogate biomarker of lupus nephropa-
thy inflammation and damage [35, 36].
On terms IgG isotype analysis, both dsDNA and
pp65422-439-specific IgG were detected in serum from
immunized animals, with IgG1 and IgG3 isotypes. Mouse
IgG3 is involved in the pathogenic autoimmunity, espe-
cially immune complex depositions and glomeruloneph-
ritis [37]. IgG3 production has been proposed as a
critical factor in nephritis among MRL/lpr mice [38].
Similar to human IgG2, T-cell-independent mouse IgG3
mainly recognizes carbohydrate epitopes [39]. Human
IgG1 and IgG2 isotypes of anti-nucleohistone and anti-
dsDNA antibodies are the predominant isotypes found
in plasma from patients with lupus who have renal
disease [40]. In pp65422-439 immunization, elevated
serum titers of anti-dsDNA IgG1 and IgG3 antibodies
positively correlated with the severity of immunoglobu-
lin deposition in glomeruli. Nevertheless, the current
study did not provide sufficient evidence to fully explain
the causal relationship between pp65-induced anti-
dsDNA antibodies and nephritis development in BALB/c
mice. The role of pp65422-439-induced autoantibodies in
glomerular injury required verification by further study.
Three dominant immunological epitopes, pp65425-434,
pp65428-437 and pp65430-439, elicited IgG and/or IgM
activities at different immunological stages. In the first
4 weeks of immunization, IgG was targeting pp65428-437.
By 8 weeks post immunization, IgG reacted to pp65425-434,
pp65428-437 and pp65430-439, likely as a consequence of
epitope spreading. After 14 weeks post immunization, IgG
remained active in response to pp65425-434 and pp65430-439
but lost its activity in response to pp65428-437. These
findings correlated with our mAb, which had reactivity to
pp65425-434 and pp65430-439. The positive response of mAb
P1 and P2 to both dsDNA and pp65430-439 suggests that
pp65430-439 may contain elements that induce the anti-
dsDNA response. The anti-dsDNA IgG activities were
detected at 4 weeks post immunization with pp65425-434
and pp65428-437. As mAb P3 and P4 did not possess anti-
dsDNA activity, this implies a strong association between
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anti-pp65428-437 activity was well-aligned with anti-dsDNA
responses, as seen at weeks 4, 8 and 14 post immunization
(Table 2). In humans, pp65428-437 is a target for pp65 and
dsDNA-specific serum from patients with SLE. These
findings suggest that pp65428-437 is a potential candidate
epitope for promoting anti-dsDNA responses.
The issues of possible factors involved in molecular
mimicry and epitope spreading have been widely discussed.
The specific amino acid residues interacting with DNA, ar-
ginine (R), asparagine (N) and lysine (K), from either virus
or necrotic cells, for somatic mutation, occurred during
clonal expansion supports the hypothesis that peptide anti-
gen has the potential to elicit the generation of anti-dsDNA
antibody [15]. The amino acid 428-439, ASTSAGRKRKSA,
of pp65 may contain one hot spot to provoke anti-dsDNA
antibody production. However, this hypothesis cannot
fully explain the discrepancy in the function of anti-
pp65422-439 antibodies in dsDNA-positive and dsDNA-
negative patients with SLE. We speculate that genetic
background bias and preference of major histocompati-
bility complex (MHC) presentation may be together
implicated in autoantibody production and subsequent
SLE development.
Over the past few decades, study of HCMV has focused
on the high-passage HCMV strain Towne, and AD169,
and research into their potential capacity through efficient
replication in human fibroblasts. In HCMV infection, pp65
is transported into the nucleus immediately through two
nuclear localization sequences, pp65418-438 and pp65537-561
[41]. The binding of pp65 to metaphase-arrested chromo-
somes in pp65-expressing fibroblasts during virus infection
implies that pp65 may not bind to host proteins, but also
forms immune-complex to genetic materials and nuclear
components [42]. The SV40 large T-antigen of human
polyomaviruses has been demonstrated to form a T-
antigen/nucleosome complex, subsequently targeted by
host immune responses and accelerates the generation of
cross-reactive antibodies against both virus and host during
viral replication [43]. Therefore, full-length or fragmented
pp65 binding to immune-complexes formed from nuclear
binding proteins may not only be targeted by antiviral anti-
bodies but also increase the opportunity for B cell epitope
spreading and lead to autoimmunity in genetically suscep-
tible individuals. It is worth mentioning that pp65 shares
high homology among different HCMV strains and the
fragment of pp65428-437, GASTSAGRKR, is highly con-
served in HCMV strains such as Towne (pp65418-427),
AD169 (pp65428-437) and Toledo (pp65428-437).
In patients with SLE, dsDNA-reactive IgM has been
proposed as a protective mechanism that ameliorates
autoimmunity and exhibits a negative association with
lupus nephritis [44]. Up to now, three possible hypotheses
have been proposed to explain how IgM antibodymodulates autoimmunity. First, the elevated titer of IgM
antibody acts as a competitive role binding to circulating
antigens to decrease the formation of the IgG immune
complex [45]. Second, IgM antibody downregulates auto-
reactive B cells to reduce the secretion of pathogenic IgG
antibody [46]. Third, the uptake of IgM immune complex
by phagocytic cells is more effective in preventing glom-
erular deposition of immune complex [47]. In pp65422-439
immunization, after immunization IgM initially targets
the entire pp65422-439 with elevated titers to pp65425-434.
Elevation of IgM to pp65428-437 at 8 weeks post
immunization was detected after major elevation of IgG
response to the same epitope. The IgM response to
pp65428-437 is linked to anti-dsDNA activities (Additional
file 4: Figure S3). However, after autoreactive anti-pp65428-
437 IgG production, the upregulated IgM subsequently re-
duced anti-pp65428-437 IgG levels, suggesting that pp65428-
437-specific IgM may be involved in alleviating the auto-
immune response through the immune system in the
non-autoimmune strain of BALB/c mice. More studies are
needed to test the correlation between different classes of
Ig and immune responses to specific autoantigens.
Conclusions
In conclusion, we report here that following immunization
of HCMV pp65422-439, which is an 18-amino-acid peptide,
non-autoimmune-prone animals developed autoimmun-
ity, and exhibited autoantibodies to nuclear components
and early signs of nephritis that resemble human SLE.
The epitope pp65428-437 is the most likely candidate to
trigger autoimmunity. The occurrence of epitope spread-
ing in HCMV infection may be a driving force to induce
cross-reactive autoantibodies in individuals with genetic
predisposition. The amelioration of autoimmunity after
elevated production of IgM targeting pp65428-437 may be
ascribed to the modulation of pathogenic autoreactive IgG
response.
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